Tragom priopćenja Actavisa da privremeno izlazi iz procesa preuzimanja Plive iz izvora bliskih islandskoj farmaceutskoj kompaniji doznajemo da Actavis u ovom trenutku među ostalim razmatra opciju da ostane najveći pojedinačni dioničar.

Actavis bi u tom slučaju, saznajemo, zatražio podrobnu internu i vanjsku istragu vezanu uz proces preuzimanja Plive koji se odvija proteklih mjeseci. Takav bi zahtjev bio u skladu sa zakonom o preuzimanju dioničkih društava.

Uh, oh, cini se da se islandjanima ne svidjaju nase balkanske metode prodaje ispod tezge… mogla bi pliva neke kostati i vise od brkova… hehe, mozda recimo glave[smiley2]

Evo malo detaljnije:

Actavis Won’t Raise Pliva Bid, Clearing Way for Barr (Update4)

Sept. 18 (Bloomberg) — Actavis Group hf, the Icelandic maker of generic heart and flu drugs, won’t raise its $2.5 billion bid for Pliva d.d., letting for Barr Pharmaceuticals Inc. to buy eastern Europe’s largest drugmaker after a three-month fight.

Actavis said it wouldn’t raise its 795 kuna a share offer because the price was too high. That leaves Barr’s bid of 820 kuna as the highest for Zagreb, Croatia-based Pliva. Barr made its latest offer Sept. 8, the seventh in its contest with the Icelandic drugmaker.

Barr is paying a high price, analysts say, to become the third-biggest generic-drug company behind Israel’s Teva Pharmaceutical Industries Ltd. and Switzerland’s Novartis AG. Barr would get access to markets such as Russia, where the government is considering raising health-care spending by 32 percent next year, according to Citigroup Investment Research.

“This is going to be an absolutely pyrrhic victory for Barr,” said Frances Cloud, an analyst at Nomura Code in London who covers Pliva. “They’re overpaying for an asset, the quality of which they are dramatically overestimating and have no ability to manage.”

Barr’s offer values Pliva at 15.6 times the Croatian company’s earnings before interest, taxes, depreciation and amortization, according to Hypo Alpe-Adria Bank data. France’s Sanofi-Aventis SA paid 15.3 times EBITDA for its 24.9 percent stake in Prague’s Zentiva NV in March. Novartis paid 11.7 times EBITDA for Slovenia’s Lek d.d. in 2002.

Trailing Rivals

Pliva, whose pretax profit margins on generics are about 10 percent, about half the level of its regional peers, will dilute Barr’s margins, she added.

“If Barr wants to overpay for Pliva, there’s nothing we can do,” Actavis Chief Executive Officer Robert Wessman said today in an interview. His company would have been able to cut more costs than Barr, and could have afforded a higher bid, he said. “We will continue to watch Pliva.”

Pliva will allow Woodcliff Lake, New Jersey-based Barr to gain in the market in western Europe, where governments are turning to generic copies of brand-name drugs to rein in health- care spending. The world market for generics, now worth $58 billion, may grow to $100 billion by 2010, according to market researcher Datamonitor.

“Our offer demonstrates our belief in the power of this combination,” Barr spokeswoman Carol Cox said in an e-mailed statement. Barr intends to “move as rapidly as possible to the closing.”

Pliva’s global depositary receipts sank $1.32, or 4.6 percent, to close at $27.53 in London. Shares in Pliva closed down 3 percent at 810.30 kuna in Zagreb. Actavis closed up 0.2 krona, or 0.3 percent, at 64.5 krona in Reykjavik. Barr shares rose 31 cents, or 0.6 percent, to $54.06 at 11:40 a.m. in New York Stock Exchange trading.

Coming Back?

The Icelandic drugmaker said it would reserve the right to re-enter the bidding at a later date, and would continue to pursue “other opportunities,” without giving details.

Actavis makes generic versions of Endo Pharmaceuticals Holdings Inc.’s Symmetrel flu treatment and Boehringer Ingelheim GmbH’s Mobic tablets for rheumatoid arthritis.

Cloud said Actavis may try to acquire Stada Arzneimittel AG, Germany’s third-biggest maker of generic drugs. It might also set its sights on Zentiva, eastern Europe’s fourth-biggest drugmaker, increasing its presence in countries such as Russia and Romania, where demand for generics is high, Cloud said. Actavis recently acquired drugmakers in Romania, the Czech Republic and India.

Ne znam za ostale ali ja cu dati svoj obol da otezam Actavisu… oni misle da barr nece uspjeti utjerati 50 posto pa da ce oni proc jeftino? Oce k…., ja svoju bijedu sutra prepisujem Barru pa cemo vidjeti cija majka crnu vunu prede[smiley2]

Nathane, zbilja prodaješ ili zezaš?

Koliko god iznosili različite moguće scenarije o daljnjem tijeku ove trakavice, (imam i ja jedno tri vrlo moguća i realna scenarija) ostaje nepobitna činjenica da je Actavis povukao ponudu (i bankovne garancije).
Barr je dao obvezujuću ponudu koja važi do uključivo 10.10. a zadnji dan za predaju dionica na pohranu za one koji će je prihvatiti je 04.10.
Sve ostalo je čista špekulacija.
Pozdrav

Slazem se s Nathanom. Da ja da imam Plivu sutra bi je prodao. To je sigurno.

Tko spominje prodaju? Samo sam rekao pomoci Barru da dodje do 50 posto

Zadnji dan Barrove ponude je 11.10. Ako do tada ne skupi 50% a neće ponuda je nevažeća i opet smo na početku. Država bi bila blesava da prodaje samo jednom ponuđaču već bi ako prodaje trebala postaviti cijenu i prodavati na burzi. Uz malo sreće Čova je zaradio paricu ostali isto a “Barr i Actavis” mogu preuzimati jedni druge. Nemaju oni menađera s brkovima i ljuibtelje opere.

Drugovi penzioneri zima će biti duga. ( love nema ali prije izbora rata je sigurna )

A ako se najveci dionicar Actavis odluci prodati svoje dionice Barru? Pristojnu svoticu bi zaradili u par mjeseci. Kako je krenulo, sve je moguce.[smiley10]

znance, ukrao si mi rijeci iz usta. bas sam ovaj scenario danas raspravljao sa jednim kolegom s foruma. a on ne vjeruje da je to moguce. [smiley1]. mislim da bi bilo mrtvih

Sve je moguće, ali čini mi se da ipak neće doći do takvog raspleta…osim toga da je netko ponudio 820 kn za plivu u ožujku svi bi pristali. ne treba biti pohlepan.

Ah vidim da je krenula nostradamus povorka… buhu brko bu nas opet sve za*ebal zar ne? E pa cisto sumnjam ovaj put.. ne vidim nacin na koji Barr nece uspjet skupiti 50 posto… kao i uvijek opet je kriv prokleti PBZ, da nisu prodali svoj udio (kojeg su imali vise nego dozvoljenih 5 posto) i usput ostetili vlastite dionicare nista od ovog se nebi niti desilo… [smiley6]